Pharmacoeconomic Guidelines: Brazil
Country/Region: Brazil
PE Guidelines
Methodological Guidelines: Economic Evaluation of Health Technologies (2014)
PDF in Portuguese
PDF in Portuguese
PE Guidelines Source:
Brazil Ministry of Health
http://www.saude.gov.br
http://www.saude.gov.br
Information current as of Monday, January 15, 2018
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | PE Guidelines |
| Title and year of the document | Methodological Guidelines: Economic Evaluation of Health Technologies (2014) |
| Affiliation of authors | Universities, government. |
| Purpose of the document | Contribute to the standardization of the local studies in order to improve transparency, review and reproduction of them. |
| Standard reporting format included | Yes |
| Disclosure | Yes |
| Target audience of funding/ author's interests | Either those who conduct HE evaluation or those who evaluate such studies (decision makers) |
| Perspective | Preferably the one of the public payer. Societal perspective also possible |
| Indication | Approved indications |
| Target population | Clearly specified |
| Subgroup analysis | When either there is a group of similar alternatives or a variability in clinical practice among a subgroup of patients |
| Choice of comparator | Most prevalent treatment in the public system, most used treatment |
| Time horizon | It must have as a basis the natural history of the disease in order to capture all relevant costs and consequences |
| Assumptions required | Yes |
| Preferred analytical technique | Cost-consequence Analysis, CMA, CEA, CUA, CBA |
| Costs to be included | It depends on the perspective of the study: direct costs with/without indirect costs. |
| Source of costs | Government databases and other public databases when necessary |
| Modeling | Yes |
| Systematic review of evidences | Yes |
| Preference for effectiveness over efficacy | Yes. Efficacy has to be converted into effectiveness by means of appropriate methods. Details must be provided. |
| Preferred outcome measure | Effectiveness |
| Preferred method to derive utility | standard gamble, time trade-off, personal trade-off or visual analogue scale. |
| Equity issues stated | Yes |
| Discounting costs | Base case: 5% (0%-10% in S.A.) |
| Discounting outcomes | Base case: 5% (0%-10% in S.A.) |
| Sensitivity analysis-parameters and range | For all uncertain parameters, a plausible range must be defined for each parameter. A 2nd order Monte Carlo simulation to be used when applicable. |
| Sensitivity analysis-methods | One-way, multi-way, probabilistic analysis |
| Presenting results | The report has to be clear, detailed and transparent. A 3-page executive summary must be written in a context accessible to a non-technical reader. |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Yes; details must be provided. |
| Financial impact analysis | Yes |
| Mandatory or recommended or voluntary | Recommended |
Acknowledgement: